A BUTYRATE STORY, IN A POWDER FORMAT
Bring gut wellness into the formulation conversation.
Tributyrin, also called glyceryl tributyrate, is a glycerol ester of butyric acid. Each molecule contains three butyrate groups linked to a glycerol backbone. That chemistry makes it a different ingredient presentation from free butyric acid or mineral butyrate salts.
Our portfolio includes tributyrin in a microcapsule powder format. The supplied technical material describes 48–52% tributyrin, a free-flowing powder and a low-odor presentation. These features make it a candidate for evaluation in capsules, tablets and powder-based supplement concepts.
01
Gut wellness concepts
Develop a product story around butyrate biology and the relationship between nutrition and the intestinal environment.
02
Microbiome-oriented formulas
Explore combinations with other ingredients in a microbiome-focused portfolio, with compatibility and evidence assessed for the complete formula.
03
Metabolic wellness research
Review the wider literature on butyrate and metabolic signaling while keeping the evidence for each chemical form and study population distinct.
UNDERSTANDING THE INGREDIENT
Tributyrin is a source of butyrate.
Butyrate is a short-chain fatty acid associated with intestinal biology. Dietary fiber fermentation by gut microorganisms is one route by which it is produced. Tributyrin offers a separate chemical route: its ester bonds can be hydrolyzed by digestive lipases to release butyric acid and glycerol.
- 01
A defined ester structure
Three butyrate groups are joined to one glycerol backbone. Tributyrin is chemically distinct from sodium butyrate and calcium butyrate.
- 02
Enzymatic hydrolysis
Digestive enzymes can break the ester bonds and liberate butyrate. The behavior of a formulated ingredient depends on its composition and digestion conditions.
- 03
A formulation to evaluate
Encapsulation and the final dosage form affect what must be tested. Release location, duration and performance require evidence for the actual system.
For a brand or formulator, the useful question is how the chosen ingredient presentation fits the intended product. The molecular rationale, the powder specification and the finished formulation each contribute different information to that assessment.
WHY A MICROCAPSULE FORMAT?
A different starting point for solid formats.
Powder handling
The supplied material describes a white to light-yellow, free-flowing powder. Assess flow, mixing and fill behavior using the proposed commercial grade under your processing conditions.
Sensory profile
The product presentation is described as low odor, with a mild fatty aroma. Sensory performance in the finished formula should be part of sample evaluation, especially for powders intended to be tasted.
Encapsulation system
The microcapsule presentation combines tributyrin with an encapsulating matrix. Request the full composition and relevant supporting release or stability information for the grade under discussion.
Format flexibility
Capsules, tablets and powder blends are candidate development directions. Softgel compatibility or other specialized uses require a separate assessment of the filling system and process.
Appearance and handling descriptions come from supplied product material. Confirm current specifications and sample performance. Gastric resistance and targeted or sustained release are not established by the format name alone.
RESEARCH CONTEXT
Separate the molecule, the model and the product.
Intestinal development and barrier-related measures
Research in pre-weaned dairy calves examined tributyrin, intestinal development, microbiota and barrier-related endpoints. It provides preclinical context for interest in the ingredient; animal feeding results do not establish effects in people.
Animal Nutrition · View the studyDigestive health endpoints
A six-week randomized, double-blind, placebo-controlled study of the branded ButyraGen® complex enrolled 596 participants and reported improvement in self-reported belly pain, particularly in women. Only 37% met its modified per-protocol criteria, which is an important interpretation limit.
Nutraceuticals · View the studyThe human study tested another supplier’s specific formulation, not Olikong’s powder. Butyrate salts, tributyrin and different delivery systems should not be treated as interchangeable clinical evidence. The studies above do not establish therapeutic or finished-product claims for this ingredient.
THE TECHNICAL PROFILE
Give your team a clear formulation basis.
- Ingredient
- Tributyrin / glyceryl tributyrate
- CAS number of tributyrin
- 60-01-5
- Molecular formula of tributyrin
- C₁₅H₂₆O₆
- Supplied format
- Microcapsule powder
- Tributyrin content
- 48–52% in supplied material; confirm current specification
- Appearance
- White to light-yellow powder, as described in supplied material
- Candidate formats
- Capsules, tablets and powder blends, subject to evaluation
- Composition & quality limits
- Request the current specification and available COA
Read the content on the correct basis
The percentage refers to tributyrin in the whole powder. As a simple mass calculation, 500 mg of a hypothetical 50% powder contains 250 mg of tributyrin. This is not a recommended serving, a measurement of absorbed butyrate or a substitute for product-specific release data. Our tributyrin content guide explains the distinction.
Define the sample evaluation
Share the target format, other formula components, processing conditions and desired sensory profile. Request the carrier composition, content assay, packaging and storage information, then agree on which stability, compatibility or release questions need a trial.
Move from ingredient to development project
For a customized presentation or an application-development brief, visit our CDMO Service. We can discuss the target specification, encapsulation requirements, test plan and scale-up questions as part of a defined project scope.
Prepare a productive technical enquiry.
- Destination market, target consumer group and product concept
- Preferred dosage form, estimated quantity and development timeline
- Current composition, specification, content method and COA requirements
- Sample tests for handling, sensory profile and compatibility
- Evidence needed for any proposed stability or release statement

